EPIDEMIOLOGY/GENETICS/CLINICAL FEATURES {#S1}
=======================================

The genetic polycystic kidney diseases of childhood (reviewed here are: autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD). ADPKD (OMIM 173900; 613095), is the most common inherited human renal disease. Approximately 85% of ADPKD cases are caused by mutations in *PKD1* on chromosome 16, and 15% are caused by mutations in *PKD2* on chromosome 4. ADPKD is generally a late-onset, systemic disease characterized by bilateral, progressive enlargement of focal fluid filled cysts occurring in all nephron segments with variable extrarenal manifestations. Extrarenal manifestations include cystic lesions in the liver, pancreas, spleen, and seminal vesicles, vascular abnormalities, including intracranial aneurysms (ICAs), dilatation of the aortic root, and dissection of the thoracic aorta, mitral valve prolapse, abdominal and inguinal hernias, and early onset hypertension ([@R1]).

Cysts in ADPKD kidneys form in utero ([@R2], [@R3]) and clinical manifestations are increasingly being recognized in newborns, children, and adolescents. These include left ventricular hypertrophy with or without systemic hypertension, proteinuria, hematuria, nephrolithiasis, flank pain, and impaired renal function ([@R3]--[@R5]). A recent study of 52 consecutively identified pediatric ADPKD patients (mean age 10±4 years; range 1--17), confirmed the presence of clinically relevant renal manifestations of ADPKD. Hypertension, albuminuria or renal insufficiency was present in 77% of these patients ([@R6]).

The clinical spectrum of pediatric ADPKD ranges from a rare, severe neonatal presentation indistinguishable from ARPKD, to symptomatic disease noted above, to asymptomatic unilateral or bilateral renal cysts in normal or enlarged kidneys detected by ultrasonography that remains clinically silent well into adulthood. Although all races and both sexes are equally affected, in adults the renal phenotype may be more severe in males, with liver manifestations more severe in females. ADPKD affects approximately 600,000 individuals in the USA and 13 million individuals worldwide and accounts for 4--6%, of the ESRD population in the U.S and over \$1.5 billion in costs per year ([@R7]).

Recent studies in experimental models ([@R8]) and molecular screening of two consanguineous families indicate that some mutated alleles retain partial activity (hypomorphs) ([@R9]). These and other data demonstrate that level of gene expression, modifying genes or untranslated mRNA (i.e., miRNA) may also play a significant role in disease expression and progression of ADPKD ([@R10]).

ARPKD (OMIM 263200) belongs to a group of congenital hepatorenal fibrocystic syndromes and is a cause of significant renal and liver-related morbidity and mortality in children. ARPKD occurs less frequently (1:20,000 live births) than ADPKD, is commonly diagnosed in utero or at birth, and occurs as a result of mutations in a single gene, *Polycystic Kidney and Hepatic Disease 1* (*PKHD1*) ([@R11], [@R12]). The carrier status is estimated at 1 in 70 ([@R13]). Severely affected fetuses display a "Potter-like" oligohydramnios phenotype with lethal pulmonary hypoplasia, and massively enlarged echogenic kidneys which can compromise normal delivery. Improved neonatal and pediatric nephrology intensive care, and enhanced disease recognition have increased survival of the newborns, but death still occurs in 25--30% of affected neonates due to respiratory insufficiency ([@R14], [@R15]).

Nearly 50% of affected individuals surviving the neonatal period progress to ESRD within the first decade of life ([@R14], [@R16]). Liver disease is an invariable feature of ARPKD and in some cases it can be a predominant clinical feature. Of all ARPKD neonatal survivors, it is estimated that 40% have severe dual organ disease, with the remainder equally divided into those with severe kidney/mild hepatobiliary disease; mild kidney /severe hepatobiliary disease, and mild dual organ involvement ([@R13], [@R17], [@R18]). The 15-year survival of patients surviving the first year of life is projected to be \>85% ([@R5], [@R15]). Despite improved survival, morbidity of this dual-organ disease is significant due to: a) renal collecting duct ectatic cysts and marked renal enlargement leading to hypertension and progressive renal failure, and b) biliary dysgenesis leading to abnormal bile duct formation with progressive periportal congenital hepatic fibrosis (CHF). Patients with CHF develop portal hypertension with resulting esophageal or gastric varices, enlarged hemorrhoids, splenomegaly, hypersplenism, protein losing enteropathy and gastrointestinal bleeding ([@R15]). In addition to CHF, non-obstructed dilation of the intrahepatic bile ducts (Caroli's syndrome) and dilation of the common bile duct occur in over 30% of ARPKD patients. The resultant abnormal hepatobiliary drainage contributes to a significant risk of ascending cholangitis with sepsis. Further, cholestasis may lead to malabsorption of fat soluble vitamins (K, D, E, A), and the overall abnormal proliferation of biliary cells has reportedly led to benign or malignant tumors in older patients. Management of portal hypertension may require endoscopic band ligation of esophageal varices or porto-systemic shunting. In the most severe instances of intractable portal hypertension, or severe dual renal and hepatobiliary disease, hepatic or dual renal-hepatic transplantation has become a viable option ([@R18]--[@R20])

Mutation analysis of the *PKHD1* gene has shown that ARPKD may present in individuals older than age 20, a finding which has significantly broadened the clinical spectrum of the disease ([@R21]). A recent report describes a 77 year old asymptomatic patient who died with autopsy findings diagnostic of ARPKD/CHF ([@R22]).

CELLULAR PATHOPHYSIOLOGY and TRANSLATIONAL IMPLICATIONS {#S2}
=======================================================

The gene product of *PKD1*, polycystin-1 (PC1), is a 467 kDa receptor-like integral membrane protein containing a long N-terminal extracellular domain ([@R23]). It is predicted to be involved cell--cell-matrix interactions and also plays a role in calcium homeostasis through its physical interaction with polycystin 2, the protein product of *PKD2* ([@R24]). PC1 interacts with the *PKD2* gene product, polycystin-2 (PC2), via a short cytoplasmic C-terminus ([@R25]) to form a heterodimeric complex. PC1 is expressed throughout the body, including abdominal organs (kidney, liver, and pancreas), heart and vasculature.

*PKD2* encodes a much smaller, 110kD, 968-amino acid polypeptide, polycystin-2 (PC-2) ([@R26]). PC2, also called TRPP2, is a calcium permeable, non-selective cation channel ([@R27]) that increases membrane permeability to Ca2+ and plays an essential role in polycystin-1 localization and function ([@R28]). PKD2 is generally a milder clinical disease than PKD1 due to the in utero development of fewer cysts in PKD2 rather than differences in the rate of cyst growth ([@R29]).

The ARPKD disease gene, *PKHD1* encodes a 67-exon mRNA and is predicted to encode a protein of 4,074 amino acids called fibrocystin or polyductin ([@R11], [@R12]). Fibrocystin represents a novel integral membrane protein with an extensive, highly glycosylated N-terminal extracellular region, a single transmembrane-spanning domain, and a short cytoplasmic tail containing potential phosphorylation sites, a Ca2^+^ binding site and a coiled coil domain that is responsible for numerous protein--protein interactions ([@R12]).

Despite the identification of the causative genes responsible for ADPKD and ARPKD, the precise function of these genes and their protein products is still unclear. (This is due in part to many novel attributes of the genes: i) the complexity of their protein structures; ii) the large size of *PKD1* and *PKHD1*; iii) the multiple transcripts produced by these genes; iv) the multiple intracellular sites of the PKD proteins; and v) these proteins' participation in a number of multimeric protein complexes.) The lack of functional PC1, PC2 or fibrocystin is embryonically lethal indicating that these proteins are essential, and that PKD begins in utero ([@R30]). Studies from multiple labs and multiple models demonstrate that ADPKD and ARPKD share common phenotypic abnormalities and intersecting signaling pathways whose disruption leads to cyst formation ([@R5], [@R15], [@R28], [@R31]).

Multiple studies have demonstrated that the protein products of the *PKD1, PKD2* and *PKHD1* genes as well as other proteins involved in renal cyst formation exist in multimeric protein complexes ([@R15], [@R25], [@R32]--[@R34]). These large multimeric "cystoprotein complexes" normally exist at specific intracellular locations within renal epithelia. These sites include the apical cell membrane (particularly in, on or adjacent to the primary cilium), adherins junctions, desmosomes, and focal adhesions. These protein complexes interact with multiple signaling pathways that are critical in maintaining normal tubular growth and differentiation. Functional changes in the structure and function of these complexes can occur if any of the individual protein components are altered. Mutations that modify cystoprotein complexes ultimately result in aberrant integration of complex signaling events and PKD.

Cyst initiation and expansion is a complex process characterized by abnormalities in tubular cell proliferation, fluid secretion, extracellular matrix formation, and cell polarity of specific proteins ([@R35]). It is also characterized by an imbalance between cellular proliferation and apoptosis. These fundamental processes are unbalanced in cystic kidneys.

Despite the lack of understanding of the precise molecular mechanisms by which mutations in *PKD1, PKD2* and *PKHD1* result in renal cyst formation, a number of common phenotypic abnormalities have been identified. These common phenotypic abnormalities define key pathogenic features of a unique phenotype of a cystic renal epithelial cell ([@R5], [@R15]). The unique "cystic phenotype", is characterized by: quantitative and qualitative abnormalities in expression and function of the epidermal growth factor (EGF) family of receptors and ligands (EGFR axis);aberrant c-AMP-signaling resulting in proliferation and decreased intracellular calcium;abnormal activity of c-Srcabnormal structure and/or function of the primary cilia;alterations in planar cell polarity (PCP)alterations in cell-cell, and cell-matrix interactions.

The first three of the phenotypic features noted above are clearly mechanistic while the others appear to be associative. Further, the mechanistic abnormalities are those most likely to be amendable to translational pharmacological therapy and are therefore discussed in further detail.

Detailed Analysis of the Unique Phenotype of the Cystic Epithelial Cell {#S3}
-----------------------------------------------------------------------

Mechanistic features of the cellular phenotype lead to the characteristic pathological features of cystic epithelia: a switch from well-differentiated, non-proliferative, resorptive epithelia to partially dedifferentiated, secretory epithelia characterized by specific polarization defects and high rates of proliferation and apoptosis ([@R15], [@R33], [@R36]). This is a critical functional change, since mathematical modeling of renal epithelia determined that proliferation and secretion are necessary and sufficient to account for cyst growth in PKD ([@R37]).

Epidermal Growth Factor Receptor (EGFR-Axis) Mediated Proliferation and Secretion {#S4}
---------------------------------------------------------------------------------

Despite the complexities of the pathogenesis of cyst formation, cystic epithelia share common phenotypic abnormalities in spite of the different genetic mutations that underlie the diseases ([@R15]). Evidence from multiple laboratories demonstrate a significant role for abnormalities in the EGFR-axis in promoting epithelial hyperplasia and ensuing renal cyst formation and progressive enlargement in both murine and human ADPKD and ARPKD ([@R38]--[@R41]).This is shown schematically in [figure 1](#F1){ref-type="fig"}. Renal cystic epithelium demonstrate both quantitative (overexpression) and qualitative (mislocalization) of one or more members of the EGFR family of receptors (EGFR1, ErbB2 and ErbB4) and EGF-related ligands (EGFR axis or ErbB axis). Overexpression includes increased mRNA, increased protein and increased activity or phosphorylation of the receptor resulting in activation of multiple signaling pathways including the MAPK pathway leading to increased proliferation ([@R13], [@R15]). In addition, evidence from rodent models suggests that similar abnormalities of the EGFR axis may mediate the biliary epithelial hyperplasia and biliary ductal ectasia in ARPKD ([@R41]--[@R44]).

In addition, cyst fluid of ADPKD patients contains mitogenic concentrations of EGFR axis ligands, which are secreted into the lumen of cysts in amounts that induce cellular proliferation ([@R45]--[@R48]). In human ADPKD and ARPKD as well as all animal models studied to date, abnormalities in the expression and localization of members of the EGFR axis have been reported. The apically expressed EGFR in cystic renal epithelia have been shown to specifically bind EGF/TGF-α with high affinity, autophosphorylate, and generate mitogenic signals in response to EGF and/or cyst fluid *in vitro* ([@R40]).

A role for increased EGFR tyrosine kinase activity in the formation and growth of renal cysts *in vivo* was firmly established by directly correlating cyst formation and growth with EGFR activity (phosphorylation levels). EGFR specific tyrosine kinase inhibitors (TKI's) either alone ([@R44]) or in combination with inhibitors of ligand availability ([@R41], [@R49]) demonstrated a direct correlation between reduced cyst formation and decreased EGFR activity (autophosphorylation).

Genetic complementation proved the mechanistic role of the abnormal EGFR-axis phenotype in cystic disease. It was achieved by introducing a mutant EGFR with decreased tyrosine kinase activity, the wa2 mouse, ([@R50]) via breeding into a murine model of ARPKD ([@R39], [@R51]). This complementation demonstrated that the mutated form of the EGFR could block the increase in EGFR-specific tyrosine kinase activity that normally accompanies the development of renal cysts in PKD, and correlated directly with an improvement in kidney function and a substantial decrease in cyst formation in the renal collecting ducts. These data unequivocally establish a primary mechanistic role for the overexpression of the tyrosine kinase activity of the EGFR in the pathophysiology of renal cyst formation.

Similar *in vivo* therapeutic targeting of substrates downstream from the EGFR such as MAPK/ MEK5/ ERK5/ MEK1/2 were effective in ameliorating biliary ductal cysts of the orthologous *Pkhd1* PCK rat ([@R43]). Such data demonstrate analogous roles of abnormalities of the EGFR-axis in both biliary and renal phenotype of ARPKD.

Since renal cyst fluid contains biologically active EGF and transforming growth factor-α, ([@R52], [@R53]), it is possible that the increased EGFR tyrosine kinase activity in the collecting tubule is part of an autocrine/paracrine cycle that drives the cellular proliferation required for cyst growth ([@R54]). By analogy, one might suspect similar EGFR-ligand abnormalities in ARPKD biliary secretions. This is currently a focus of investigation in our laboratory.

*In vitro* studies using PKHD1-silenced HEK-293T cell lines demonstrated that these cells were hyperproliferative to EGF stimulation, which lowered intracellular \[Ca2+\]i and caused EGF-induced increased ERK1/2 activity ([@R55]). An increase of intracellular \[Ca2+\]i in PKHD1-silenced cells repressed the EGF-dependent ERK1/2 activation and the hyperproliferative response to EGF stimulation. Thus, inhibition of PKHD1 can cause EGF-induced excessive proliferation through decreasing intracellular \[Ca2+\] i, resulting in EGF-induced ERK1/2 activation. These studies suggest that loss of fibrocystic leads to abnormal proliferation in kidney epithelial cells and cyst formation in ARPKD via modulation of intracellular \[Ca2+\] levels. As noted below, decreased \[Ca2+\]i is also a key feature of fluid secretion ([@R56], [@R57]).

Multiple studies have demonstrated that collecting duct cells (CD) elevate \[Ca2+\] in response to flow across the cell surface and this response has been attributed to PC1 and PC2 interactions in the primary cilia ([@R58], [@R59]). However, intercalated cells, which lack primary cilia, respond to mechanical flow changes with comparable increases in \[Ca2+\]i that is observed in principal cells, which have primary cilia ([@R60], [@R61]). Other TRP channels have been identified in CD cells and TRPV4 channels have been shown to respond to mechanical stimulation ([@R62]). Additionally, TRPV4 channels are essential for flow induced \[Ca2+\] even in the presence of PKD2 suggesting that TRPV4 channels are responsible for the mechanosensitive properties of CD cells ([@R63], [@R64]).

cAMP Mediated Proliferation and Secretion {#S5}
-----------------------------------------

A second major contributor to renal epithelial cellular proliferation and secretion in both ADPKD and ARPKD is the adenylyl cyclase adenosine 3′, 5′-cyclic monophosphate (cAMP) pathway shown in [figure 2](#F2){ref-type="fig"}. G protein-coupled vasopressin V2 receptors in the renal collecting duct regulate aquaporin 2 water channels, and the activity of adenylyl cyclases which in turn play a role in mediating intracellular cAMP levels.

In normal human and mouse renal epithelial cells, cAMP has been shown to inhibit the Ras/Raf-1/MEK/ERK pathway at the level of Raf-1 and to inhibit cell proliferation. In contrast, cAMP has been shown to stimulate β-Raf (via c-Src dependent phosphorylation) and activate the MEK/ERK pathway in ARPKD and ADPKD cells leading to increased cell proliferation ([@R65]--[@R69]). Therefore, cAMP can act to stimulate or inhibit proliferation depending on intra-cellular conditions. This phenotypic shift in response to cAMP appears to involve cross-talk between cAMP, Ca2+ and c-Src signaling to β-Raf, a kinase upstream of the MEK/ERK pathway ([@R57], [@R70]). In normal cells, β-Raf is repressed by Akt (protein kinase B), a Ca2+-dependent kinase, preventing cAMP activation of ERK and cell proliferation. In PKD epithelia from either ARPKD or ADPKD kidneys, low Ca2+ levels and c- Src-dependent phosphorylation of β-Raf result in an increased expression of cAMP as well as a switch in cAMP from an antiproliferative signaling molecule to a pro-mitogenic stimulus that activates the MEK/ERK pathway and promotes cellular proliferation and secretion ([@R57], [@R70]).

The switch in cAMP from an anti-mitogen to a mitogenic stimulus has been shown to be directly correlated with intracellular calcium levels \[Ca2+\]i ([@R68]). Pharmacological elevation of Ca2+ increases p-Akt levels, whereas Ca2+ channel blockers decrease phospho-Akt ([@R69]). This observation that the reduction of intracellular \[Ca2+\]i in M-1 or NHK cells with calcium channel blockers replicates the abnormal proliferative response of PKD cells to cAMP establishes a link between the PKD proliferative phenotype, reduction in \[Ca2+\]i, and cAMP activity ([@R70]).

Evidence for the role of \[Ca2+\]i-mediated proliferation has been further strengthen by studies showing that the elevation of \[Ca2+\]i levels in ADPKD and ARPKD cultured cells increases Akt activity and blocks cAMP-dependent β-Raf and ERK activation ([@R69]). The study has also demonstrated that increases in \[Ca2+\]i restore the normal anti-mitogenic response to cAMP in renal cells derived from either human ADPKD or ARPKD kidneys.

These data suggest that the PKD proteins (PC1, PC2, and fibrocystin) play a role in maintaining Ca2+ homeostasis. Mutations in any of the PKD proteins may lead to reduced \[Ca2+\]i and activate the cAMP mitogenic pathway.

Mechanisms of Fluid Secretion-a Key Feature Differentiating ADPKD from ARPKD {#S6}
----------------------------------------------------------------------------

ARPKD cysts have a fundamental anatomical difference from ADPKD cysts, which would suggest different secretory mechanisms. Unlike ADPKD cysts, ARPKD cysts remain open to the urinary lumen, maintaining both afferent and efferent tubular connections while ADPKD cysts rapidly "pinch-off" from urinary flow and continue to expand by transepithelial secretion as shown in [figures 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}. In ADPKD more than 70% of cysts have no afferent or efferent tubular connections ([@R71], [@R72]). Despite this anatomic difference, secretion is still a necessary element of cyst formation in both ADPKD and ARPKD. Given the structural differences one would not expect transtubular secretion to be as critical in the pathogenesis of ARPKD cysts given their continuity with urinary luminal flow.

In ADPKD, the evidence indicates that Cl- is secreted via a cAMP mediated co-transport mechanism in the basolateral membrane and CFTR in the apical membrane, leading to expansion of cysts particularly after they have detached from the nephron of origin ([@R57], [@R70], [@R73], [@R74]). This Cl- transport mechanism does not appear to be relevant in ARPKD. Using a genetic complementation approach, the BPK mouse was crossed with a CFTR knockout mouse ([@R75]). The results demonstrated that the absence of CFTR did not alter the course of renal or biliary cyst development or growth in ARPKD. Indeed, the double mutant appeared, if anything, to be larger and more cystic than cystic controls ([@R76]).

ARPKD cystic epithelia have been shown to exhibit net fluid secretion through a decrease in principal cell sodium absorption. This is due to an EGF mediated decrease in the alpha-subunit of the epithelial Na channel (ENaC) ([@R77]--[@R79]). However, conflicting data has been reported ([@R80]).

cSrc (pp66Src): Integration of EGFR axis and cAMP Mediated Proliferation and Secretory Pathways {#S7}
-----------------------------------------------------------------------------------------------

Given the complex intracellular cascades activated in both ADPKD, and ARPKD, the "holy grail" of future therapy is to identify key cellular "checkpoints" where diffuse processes responsible for the "cystic phenotype" are integrated. Given the primary roles of the EGFR-axis and adenylate cyclase mediated proliferation, targeting "upstream" events which modulate multiple signaling pathways is a particularly intriguing approach.

cSrc (pp66Src) is a key focal intermediate in several central cystogenic signaling pathways as shown in [figure 3](#F3){ref-type="fig"}. Src is a key intermediate which integrates proliferation from both G-coupled protein receptor-cAMP pathway and the EGFR-axis signaling pathways ([@R5], [@R57], [@R70]). Increased Src in PKD uncouples EGFR-ligands from peritubular matrix, reciprocally phosphorylates EGFR and is required for the phosphorylation of β-Raf allowing a normal inhibitory mechanism preventing renal epithelial proliferation to be bypassed. In animal models of PKD and human PKD, increased Src activity (pY418) was found to be associated with a more severe renal cystic disease. Furthermore, treatment of BPK mice and PCK rats with bosutinib, an inhibitor of Src, ameliorated both the renal and hepatic disease through inhibition of G-protein coupled receptor and EGFR-axis triggered phosphorylation cascades ([@R31]).

FROM PATHOPHYSIOLOGY TO CURRENT AND FUTURE THERAPIES PGD/IVF {#S8}
============================================================

A novel, reliable linkage-based protocol for preimplantation genetic diagnosis of ARPKD using single-cell multiple displacement amplification (MDA) products for *PKHD1* haplotyping has been developed that significantly decreases the problem of allelic dropout ([@R81]). This unique protocol uses whole genome amplification of single blastomeres, MDA, and haplotype analysis with 20 novel polymorphic short tandem repeat (STR) markers from the *PKHD1* gene and flanking sequences. This method enables unambiguous identification of the haplotypes of embryos produced by at-risk couples, eliminates the genetic risk (25%) of proven ARPKD carriers from having a child affected with ARPKD ([@R81]).

A similar approach to ADPKD has been published. However, the fact that many patients with ADPKD are relatively asymptomatic into adulthood raises major ethical concerns regarding this approach ([@R82])

Details regarding molecular diagnosis of ARPKD or ADPKD can be found at GeneClinics: Clinical Genetic Information Resource (online database) at <http://www.geneclinics.org>.

Dialysis and Transplantation {#S9}
----------------------------

Current therapy for ADPKD and ARPKD patients that have reached ESRD is limited to dialysis and transplantation. The treatment of dual organ involvement in ARPKD has traditionally focused first on the renal complications and sequentially on hepatobiliary complications. In many cases this approach leads to the necessity of a renal transplantation and a second transplant to deal with the severe hepato-biliary disease. A recently published article asserts that carefully chosen ARPKD patients with severe dual organ involvement (40% of all neonatal survivors, as previously noted) that ultimately require kidney transplantation would potentially benefit from dual organ (kidney and liver) transplant ([@R18]).

The authors reason that the complications of hepatic involvement (predominantly the risk of ascending cholangitis) ([@R19]) coupled with improved outcomes of liver transplantation mandate a careful assessment of risk-benefit ratio in all ARPKD patients with severe dual organ involvement. The authors assert that lower Pediatric End Stage Liver Disease/Model for End Stage Liver Disease (PELD/MELD) scores can be used to justify the benefit of combined liver--kidney transplant compared with isolated kidney transplants. The authors present a step by step algorithm designed to assist clinicians in this decision making process ([@R18], [@R19]) ([figure 4](#F4){ref-type="fig"}). A recent series of 8 ARPKD patients receiving dual renal-hepatic transplantation demonstrate the feasibility of this approach ([@R20]). In January of 2014, it seems appropriate to consider such an approach in selected patients, at least until the pharmacological, disease-specific options noted in the following section are proven safe and efficacious for ARPKD.

The delineation of the molecular and cellular pathophysiology of PKD has led to a new era of pharmacological therapeutic intervention based on targeting specific signaling abnormalities of cystic epithelia. The goal of these therapies is to prevent development or decrease progressive enlargement of cystic lesions. The major targets or strategies currently being evaluated and our assessment of their potential (based on currently available data from ongoing human trials or preclinical considerations) are noted in [Table 1](#T1){ref-type="table"}.

[Table 1](#T1){ref-type="table"} broadly summarizes pharmacological approaches which have shown significant benefit in animal models of PKD and are either currently or soon will be tested for safety and efficacy in clinical trials. It is clear that all of the therapies listed have systemic side effects. The goal of clinical trials will be to determine safe pharmacological windows where efficacy is preserved and side effects minimized.

Based on systemic toxicities and pre-clinical studies to date, no single drug alone would appear to be fully capable of slowing the progressive renal cyst growth and decreased renal function that occurs in ADPKD and ARPKD, nor the biliary dysgenesis that leads to CHF in ARPKD. Based on previously noted pre-clinical data (where the use of multiple agents reduced potential drug toxicity by 67% without a reduction in therapeutic efficacy) ([@R41]) future trials will most likely consider the use of: multiple, complementary agents;oragents that inhibit key intersecting points of abnormally active pathways (i.e., c-Src) or;inhibit multiple pathways using agents such as multi-kinase inhibitors.
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![An overview of the EGFR-axis pathway that contributes to cyst formation and progressive enlargement in ADPKD and ARPKD. Abnormal expression and apical localization of the EGF receptors in the presence of increased ligand availability due to increased activity of matrix metalloproteinase (MMP) establishes an autocrine/paracrine cycle that drives cellular proliferation. Ligand binding leads to the formation of homodimers or heterodimers that initiates autophosphorylation and activates the MAPK pathway resulting in proliferation.](nihms548721f1){#F1}

![A simplified representation of the cAMP or G-protein pathway that contributes to cyst formation and progressive enlargement in PKD. Adenylyl-cyclase activation leads to increased levels of cAMP which activates PKA. PKA activation in the presence of low intracellular calcium levels phosphorylates β-Raf in a Src-dependent process. This phosphorylated β-Raf allows the cell to bypass the normal inhibition of PKA on MAPK activation and leads to increased cellular proliferation and possibly angiogenesis via activation of Erk 1/2.](nihms548721f2){#F2}

![This represents our recent approach to the discovery and testing of potential therapeutic interventions. Our rationale is that by using a compound that inhibits both pathways, a smaller dose will be necessary to achieve maximum cyst reduction and any toxicity associated with the therapy will be minimized. cSrc provides such a target because it inhibits both the activity of the EGFR-axis and the G-protein (cAMP) pathway which are both aberrantly active in ADPKD and ARPKD. Active cSrc can: reciprocally phosphorylate EGFR, and increase availability of EGFR-axis ligands by activating matrix metalloproteinases (MMPs) necessary for ligand processing and; in the cAMP mediated pathway, cSrc is necessary for phosphorylation of β-Raf and subsequent activation of MAPK leading to increase proliferation. This diagram demonstrates the rationale for the therapeutic strategy we are pursuing, the use of therapeutic compounds that interfere with multiple pathways.](nihms548721f3){#F3}

![Algorithm to help guide clinicians in making decisions re:performing an isolated kidney transplant vs. a combined liver-kidney transplant in ARPKD/CHF patients with dual organ involvement. Reprinted with permission from ([@R18]).](nihms548721f4){#F4}

###### 

The Future: Therapies for Childhood Pkd

  ------------------------------------------------------------------------------------------------------------------------------------------
  Class\                                                         ADPKD   ARPKD   CLINICAL TRIALS or pre-clinical\
  (compound)                                                                     reference\
                                                                                 ([www.clinicaltrials.gov](http://www.clinicaltrials.gov))
  -------------------------------------------------------------- ------- ------- -----------------------------------------------------------
  VPV2R Antagonists (Tolvaptin)                                  ++/−    +/−−    Phase II--III\
                                                                                 NCT01022424 (III) in progress\
                                                                                 NCT01280721 (III) in progress\
                                                                                 NCT01214421 (III) recruiting\
                                                                                 NCT01451827 (II) recruiting

  Src Inhibitors (Bosutinib)                                     +++     +++     Phase II\
                                                                                 NCT01233869 (II) recruiting

  mTOR Inhibitors                                                +/− −   +/− −   Phase I--II\
                                                                                 NCT00414440-in progress\
                                                                                 NCT00286156\
                                                                                 NCT01009957 (II,III)-recruiting

  Multi-Kinase Inhibitors (KD-019)                               +++     ++/?    Phase I--II\
                                                                                 NCT01559363 (I--II) recruiting

  Somatostatins Long Acting analogues (Octreonide & Laneonide)   ++/?    ++/?    Phase III\
                                                                                 NCT01377246 (III) recruiting\
                                                                                 NCT01354405 (III) in progress

  (Lisinopril and Telmisartan) HALT PKD                          ++/?    ++/?    NCT00283686 (III) in progress

  (Diterpene) (Triptolide Woldifii)                              +/??    +/??    NCT00801268 (II) (China only)

  EGFR-Axis Inhibitors                                           +++     +++     ([@R40])\
                                                                                 ([@R42])

  Angiogenesis Inhibitors/MMP-inhibitors                         ++/?    ++/?    ([@R74])

  SMAC Mimetics/ HDAC-i/TNF-α                                    ++/?    ++/?    ([@R75])\
                                                                                 ([@R76])

  20-HETE                                                        ++/?    ++/?    ([@R77])\
                                                                                 ([@R78])

  ROS-i                                                          ++/?    ++/?    ([@R79])

  Manipulation of Genetic Modifiers                              ++/?    ++/?    ([@R80])
  ------------------------------------------------------------------------------------------------------------------------------------------
